DEVOPS AUTOPILOT

LIVE

Serial Number

98103538

Owner

DuploCloud, Inc.

First Use Date

Jul 1, 2023

Filing Date

Jul 26, 2023

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

DEVOPS AUTOPILOT Trademark

Serial Number: 98103538 • Registration: 7456068

DEVOPS AUTOPILOT is a trademark filed by DuploCloud, Inc. on July 26, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Trademark Classes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

DuploCloud, Inc. (4 trademarks)

San Jose, CA 95131

Entity Type: 03

Trademark Details

Filing Date

July 26, 2023

Registration Date

July 23, 2024

First Use Anywhere

July 1, 2023

First Use in Commerce

July 1, 2023

Published for Opposition

May 7, 2024

Goods & Services

Design and development of computer software for creating cloud-based infrastructure code and controls for security systems

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Jul 23, 2024 NRCC

REGISTERED-PRINCIPAL REGISTER

Jul 23, 2024 R.PR

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

May 7, 2024 NPUB

PUBLISHED FOR OPPOSITION

May 7, 2024 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Apr 17, 2024 NONP

APPROVED FOR PUB - PRINCIPAL REGISTER

Apr 2, 2024 CNSA

TEAS/EMAIL CORRESPONDENCE ENTERED

Mar 29, 2024 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Mar 29, 2024 CRFA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Mar 29, 2024 TROA

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Mar 28, 2024 GNRN

NON-FINAL ACTION E-MAILED

Mar 28, 2024 GNRT

NON-FINAL ACTION WRITTEN

Mar 28, 2024 CNRT

ASSIGNED TO EXAMINER

Mar 27, 2024 DOCK

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Aug 25, 2023 NWOS

NEW APPLICATION ENTERED

Jul 29, 2023 NWAP

Related Trademarks

More from this Owner

DUPLOCLOUD DEVOPS ON AUTOPILOT

DEVOPS ON AUTOPILOT

More in Same Class

POLLBOOK

ENGAGE IQ POST-CARE

ZEROSIC

BLUESIC

ZEUS

PIXIMUNE THERAPEUTICS